Autosomal-dominant polycystic kidney disease: perspectives of treatment
- Authors: - -
- Issue: No 3 (2011)
- Pages: 11-15
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245935
- ID: 245935
Cite item
Full Text
Abstract
Perspectives of treatment of autosomal-dominant polycystic kidney disease, especially target therapeutic strategies, are discussed
References
- Torres V.E., Harris P.C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009; 76: 149-168
- Perrone R.D., Ruthazer R., Terrin N.C. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 2001; 38: 777-784
- Parfrey P.S., Barrett B.J. Hypertension in autosomal dominant polycystic kidney disease. Curr. Opin. Nephrol. Hypertens 1995; 4: 460-464
- Schrier R.W., Johnson A.M., McFann K., Chapman A.B. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64:1792-1799
- Idrizi A., Barbullushi M., Strakosha A. et al. The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease. G. Ital. Nefrol. 2007; 24: 595-599
- Covic A., Mititiuc I., Gusbeth-Tatomir P., Goldsmith D.J. The reproducibility of the circadian BP rhythm in treated hypertensive patients with polycystic kidney disease and mild chronic renal impairment - a prospective ABPM study. J. Nephrol 2002;15: 497-506
- Chapman A.B., Johnson A.M., Rainguet S. et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1997; 8: 1292-1297
- Torres V.E., King B.F., Chapman A.B. et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2: 112-120
- Chapman A.B., Johnson A., Gabow P.A., Schrier R.W. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096
- Wang D., Iversen J., Wilcox C.S., Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388
- Chapman A.B., Stepniakowski K, Ranbari-Oskoui F. Hypertension in autosomal polycystic kidney disease. Adv. Chronic Kidney Dis. 2010 ; 17(2) : 153-163
- Kanno Y., Okada H., Moriwaki K. et al. The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats. Hypertens Res. 2002; 25(6): 939-943
- Zeltner R., Poliak R., Stiasny B. et al. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2008; 23(2): 573-579
- Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996; 334(15): 939-945
- Ulusoy S., Ozkan G., Orem C. et al. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Ren. Fail. 2010; 32(8): 913-917
- Amico P., Kalbermatter S., Kiss D. et al. Aliskiren corrects recurrent hyperreninemia and hyperaldosteronism in autosomal dominant polycystic kidney disease. Clin. Nephrol. 2009; 72(3): 237-239
- Chapman A.B. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD Studies. Clin J Am Soc Nephrol 2008; 3: 1197-1204
- Bae K.T., Commean P.K., Lee J. Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J Comput Assisted Tomogr 2000; 24: 614-619
- Grantham J.J., Torres V.E., Chapman A.B. et al. Volume progressionin polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130
- Chapman A.B., Guay-Woodford L., Grantham J.J. et al. Renal structure in early autosomal dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Kidney Int 2003; 64: 1035-1045
- Yamaguchi T., Pelling J.C., Ramaswamy N.T. et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000; 57: 1460-1471
- Masyuk A.I., Masyuk T.V., Splinter P.L, et al. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 2006; 131: 911-920
- van Keimpema L., Nevens F., Vanslembrouck R. et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009; 137(5): 1661-8.e1-2
- Hogan M.C., Masyuk T.V., Page L.J. et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J. Am. Soc. Nephrol. 2010; 21(6): 1052-1061
- Meijer E., Boertien W.E., Zietse R., Gansevoort R.T. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2011; 34(4): 235-244
- Nagao S., Nishii K., Katsuyama M. et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17(8): 2220-2227
- Chapman A.B., Torres V.E., Grantham J.J. et al. A phase IIB pilot study fof the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA) in patients with ADPKD. J. Am. Soc. Nephrol 2005; 16: 68A
- Zafar I., Tao Y., Falk S. et al. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 2007; 293: F854-F859
- van Dijk M.A., Kamper A.M., van Veen S. et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16: 2152-2157
- Leuenroth S.J., Okuhara D., Shotwell J.D. et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007;104: 4389-4394
- Rankin C.A., Itoh Y., Tian C. et al. Matrix metalloproteinase-2 in a murine model of infantile-type polycystic kidney disease. J. Am. Soc. Nephrol. 1999; 10(2): 210-217
- Obermuller N., Morente N., Kranzlin B. et al. A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol 2001; 280(3): F540-F550
- Sweeney W.E. Jr., Hamahira K., Sweeney J. et al. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003; 64: 1310-1319
- Serra A.L., Poster D., Kistler A.D. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363(9): 820-829